190 related articles for article (PubMed ID: 24014381)
1. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
MacDonald TJ; Vezina G; Stewart CF; Turner D; Pierson CR; Chen L; Pollack IF; Gajjar A; Kieran MW
Neuro Oncol; 2013 Oct; 15(10):1438-44. PubMed ID: 24014381
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
MacDonald TJ; Stewart CF; Kocak M; Goldman S; Ellenbogen RG; Phillips P; Lafond D; Poussaint TY; Kieran MW; Boyett JM; Kun LE
J Clin Oncol; 2008 Feb; 26(6):919-24. PubMed ID: 18281665
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dabrafenib in Pediatric Patients with
Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
[TBL] [Abstract][Full Text] [Related]
5. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
[TBL] [Abstract][Full Text] [Related]
7. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
Gilbert MR; Kuhn J; Lamborn KR; Lieberman F; Wen PY; Mehta M; Cloughesy T; Lassman AB; Deangelis LM; Chang S; Prados M
J Neurooncol; 2012 Jan; 106(1):147-53. PubMed ID: 21739168
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
9. Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
Lombardi G; Zustovich F; Farina P; Polo V; Farina M; Della Puppa A; Bertorelle R; Gardiman MP; Berti F; Zagonel V
Anticancer Drugs; 2012 Aug; 23(7):749-53. PubMed ID: 22382388
[TBL] [Abstract][Full Text] [Related]
10. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
Nabors LB; Mikkelsen T; Rosenfeld SS; Hochberg F; Akella NS; Fisher JD; Cloud GA; Zhang Y; Carson K; Wittemer SM; Colevas AD; Grossman SA
J Clin Oncol; 2007 May; 25(13):1651-7. PubMed ID: 17470857
[TBL] [Abstract][Full Text] [Related]
11. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Fouladi M; Nicholson HS; Zhou T; Laningham F; Helton KJ; Holmes E; Cohen K; Speights RA; Wright J; Pollack IF;
Cancer; 2007 Dec; 110(11):2535-41. PubMed ID: 17932894
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R
J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study.
Jakacki RI; Bouffet E; Adamson PC; Pollack IF; Ingle AM; Voss SD; Blaney SM
Neuro Oncol; 2011 Aug; 13(8):910-5. PubMed ID: 21764821
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.
Yerram P; Reiss SN; Modelevsky L; Gavrilovic IT; Kaley T
J Neurooncol; 2019 Oct; 145(1):57-63. PubMed ID: 31432377
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Mantica M; Pritchard A; Lieberman F; Drappatz J
J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
